

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE MONTH OF MAY 2021**

---

**COMMISSION FILE NUMBER 001-38976**

---

**Genmab A/S**

(Exact name of Registrant as specified in its charter)

**Kalvebod Brygge 43**

**1560 Copenhagen V**

**Denmark**

**+45 70 20 27 28**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)

Yes  No

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

---

---

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENMAB A/S

BY: /s/ Anthony Pagano

Name: Anthony Pagano

Title: Executive Vice President & Chief Financial  
Officer

**DATE: May 11, 2021**

---

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	Company Announcement Dated May 11, 2021: Capital Increase in Genmab as a Result of Employee Warrant Exercise
99.2	Company Announcement Dated May 11, 2021: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

---



## Capital Increase in Genmab as a Result of Employee Warrant Exercise

### Company Announcement

**COPENHAGEN, Denmark; May 11, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,418 shares as a consequence of the exercise of employee warrants.**

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

2,600 shares at DKK 40.41,  
 1,440 shares at DKK 225.30,  
 8,750 shares at DKK 337.40,  
 1,375 shares at DKK 636.50,  
 400 shares at DKK 815.50,  
 6,050 shares at DKK 939.50,  
 4,594 shares at DKK 1,032.00,  
 1,317 shares at DKK 1,145.00,  
 2,865 shares at DKK 1,210.00,  
 1,000 shares at DKK 1,233.00, and  
 3,027 shares at DKK 1,432.00.

Proceeds to the company are approximately DKK 25.6 million. The increase corresponds to approximately 0.05% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2021. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No. 1767 of November 27, 2020, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 65,620,740 which is made up of 65,620,740 shares of a nominal value of DKK 1 each, corresponding to 65,620,740 votes.

### About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit [Genmab.com](http://Genmab.com).

### Contact:

Marisol Peron, Senior Vice President, Global Investor Relations & Communications  
 T: +1 609 524 0065; E: [mmp@genmab.com](mailto:mmp@genmab.com)

Genmab A/S  
 Kalvebod Brygge 43  
 21560 Copenhagen V, Denmark

Tel: +45 7020 2728  
 Fax: +45 7020 2729  
[www.genmab.com](http://www.genmab.com)

Company Announcement no. 39  
 Page 1/2  
 CVR no. 2102 3884  
 LEI Code 529900MTJPDPE4MHJ122



## Capital Increase in Genmab as a Result of Employee Warrant Exercise

### For Investor Relations:

Andrew Carlsen, Vice President, Head of Investor Relations  
T: +45 3377 9558; E: acn@genmab.com

*This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on [www.genmab.com](http://www.genmab.com) and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at [www.sec.gov](http://www.sec.gov). Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.*

*Genmab A/S and/or its subsidiaries own the following trademarks: Genmab<sup>®</sup>; Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; DuoBody<sup>®</sup>; DuoBody in combination with the DuoBody logo<sup>®</sup>; HexaBody<sup>®</sup>; HexaBody in combination with the HexaBody logo<sup>®</sup>; DuoHexaBody<sup>®</sup>; and HexElect<sup>®</sup>*

Genmab A/S  
Kalvebod Brygge 43  
21560 Copenhagen V, Denmark

Tel: +45 7020 2728  
Fax: +45 7020 2729  
[www.genmab.com](http://www.genmab.com)

Company Announcement no. 39  
Page 2/2  
CVR no. 2102 3884  
LEI Code 529900MTJPDPE4MHJ122

---



## Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

### Company Announcement

COPENHAGEN, Denmark; May 11, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons.

Please find below a statement of such trading in shares issued by Genmab A/S

<b>1.</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Anthony Pagano	
<b>2.</b>	<b>Reason for the notification</b>		
a)	Position/status	Executive Vice President and Chief Financial Officer	
b)	Initial notification/Amendment	Initial notification	
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Genmab A/S	
b)	LEI-code	529900MTJPDPE4MHJ122	
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Share	
	Identification code	DK0010272202	
b)	Nature of the transaction	Subscription of shares (exercise of warrants)	
c)	Price(s) and volume(s)	Price(s)	
		DKK 337.40	3,500
		DKK 939.50	3,750
d)	Aggregated information - Aggregated volume - Price	7,250 shares DKK 648.83	
e)	Date of the transaction	2021-05-11	
f)	Place of the transaction	Outside a market place	



## Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

### About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit [Genmab.com](http://Genmab.com).

### Contact:

Marisol Peron, Senior Vice President, Global Investor Relations & Communications  
T: +1 609 524 0065; E: [mmp@genmab.com](mailto:mmp@genmab.com)

### For Investor Relations:

Andrew Carlsen, Vice President, Head of Investor Relations  
T: +45 3377 9558; E: [acn@genmab.com](mailto:acn@genmab.com)

*This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on [www.genmab.com](http://www.genmab.com) and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at [www.sec.gov](http://www.sec.gov). Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.*

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab<sup>®</sup>; Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; DuoBody<sup>®</sup>; DuoBody in combination with the DuoBody logo<sup>®</sup>; HexaBody<sup>®</sup>; HexaBody in combination with the HexaBody logo<sup>®</sup>; DuoHexaBody<sup>®</sup>; and HexElect<sup>®</sup>

Genmab A/S  
Kalvebod Brygge 43  
21560 Copenhagen V, Denmark

Tel: +45 7020 2728  
Fax: +45 7020 2729  
[www.genmab.com](http://www.genmab.com)

Company Announcement no. 40  
Page 2/2  
CVR no. 2102 3884  
LEI Code 529900MTJPDPE4MHJ122

